NVNO vs. CERS, TCMD, NVRO, OSUR, DRTS, RCEL, NYXH, CATX, SKIN, and BWAY
Should you be buying enVVeno Medical stock or one of its competitors? The main competitors of enVVeno Medical include Cerus (CERS), Tactile Systems Technology (TCMD), Nevro (NVRO), OraSure Technologies (OSUR), Alpha Tau Medical (DRTS), AVITA Medical (RCEL), Nyxoah (NYXH), Perspective Therapeutics (CATX), Beauty Health (SKIN), and BrainsWay (BWAY). These companies are all part of the "surgical & medical instruments" industry.
enVVeno Medical vs.
Cerus (NASDAQ:CERS) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability.
enVVeno Medical has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.
Cerus currently has a consensus target price of $3.50, suggesting a potential upside of 185.71%. Given Cerus' stronger consensus rating and higher probable upside, research analysts clearly believe Cerus is more favorable than enVVeno Medical.
78.4% of Cerus shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 3.4% of Cerus shares are held by company insiders. Comparatively, 16.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Cerus has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
Cerus received 414 more outperform votes than enVVeno Medical when rated by MarketBeat users. Likewise, 72.34% of users gave Cerus an outperform vote while only 62.65% of users gave enVVeno Medical an outperform vote.
enVVeno Medical has a net margin of 0.00% compared to Cerus' net margin of -11.60%. Cerus' return on equity of -40.55% beat enVVeno Medical's return on equity.
In the previous week, Cerus had 2 more articles in the media than enVVeno Medical. MarketBeat recorded 2 mentions for Cerus and 0 mentions for enVVeno Medical. Cerus' average media sentiment score of 0.84 beat enVVeno Medical's score of 0.44 indicating that Cerus is being referred to more favorably in the media.
Summary
Cerus beats enVVeno Medical on 13 of the 17 factors compared between the two stocks.
Get enVVeno Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVNO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
enVVeno Medical Competitors List
Related Companies and Tools
This page (NASDAQ:NVNO) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy NVNO Stock Free NVNO Stock Alerts